To report efficacy and safety of the approved IXE dose over 5 years from UNCOVER-3. (NCT01646177).Patients (N=1346) were randomized 1:2:2:2 to receive subcutaneous injections of placebo, etanercept 50 mg twice […]
-
-
Can dermatology employers require employees to receive the COVID-19 vaccine?
-
THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS
-
Expression of retinoid receptors in hand eczema.
-
S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants
-
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
